中文

2008-5-5
Our Company convened the clinical seminar of new tumor drug on 27th April, 2008
2008-3-4
the delegation of Penn EMTM program paid a visit to the company
2008-4-21
Example Project “Industrialization of high technology of humanized monoclonal antibody drug such as Recombinant Human Tumor Necrosis Factor – a Receptor II: IgG Fc Fusion Protein for Injection” passed acceptance check
2008-1-14
Three SBI titles won by the Company
2008-1-7
Company’s major projects gained the supports by “863 program” of Science and Technology Ministry

What's monoclonal antibody (mAB)?
monoclonal antibody (mAB) ?A single type of antibody that is directed against a specific epitope (antigen, antigenic determinant) and is produced by a single clone of B cells or a single hybridoma cell line, which is formed by the fusion of a lymphocyte cell with a myeloma cell. Some myeloma cells synthesize single antibodies naturally.

 




CPGJ is Focusing on biopharmaceutical products development,manufacturing,
and marketing,in china and in the world.

CPGJ targets on producing therapeutic humanized/human antibodies,vaccines,and diagnostic products for unmet medical needs,in cancer and autoimmune diseases.


 
  Yisaipu

DESCRIPTION
Proprietary Name:  Recombinant Human Necrosis Factor-αReceptorII:IgG Fc (rhTNFR:Fc) Fusion Protein for Injection
Brand Name:   Yisaipu
Composi


No.399 Libing Road,Zhangjiang Hi-tech Park,
Shanghai 201203,P.R.China
Tel : 86-021-50791399
Fax:86-021-58553335


  Copyright 2002-2006 Shanghai CP Guojian Pharmaceutical Co.,Ltd.